Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Industry-Proposed Price Maintenance System Meets No Strong Opposition at Chuikyo
December 14, 2009
- Crestor Reduces CV Events Risk in Women by 46%
December 14, 2009
- Alfresa Pharma to Expand Contract Manufacturing Business
December 7, 2009
- US GLs Recommend Effient for ACS Patients Following PCI
December 7, 2009
- Pharma Industry to Become a Major Foreign Cashcow: Dr Sakurai of DPJ
December 7, 2009
- Biosimilar of EPO Recommended for Approval
December 7, 2009
- Market Price Survey Finds Mean Yakkasa of 8.4%
December 7, 2009
- Larger Differences in Prices Necessary between Original Drugs and Generics
December 7, 2009
- Japan's 1st GLP-1 Analogue Victoza Recommended for Approval
December 7, 2009
- Amgen to File NDA for AMG531 in Early 2010
December 7, 2009
- Afinitor, Abraxan Recommended for Approval
December 7, 2009
- Janssen Signs Clinical Research Aid Agreement with Keio Univ.
December 7, 2009
- Chuikyo to Decide on Industry Proposed Drug Pricing System Reform by Year-End
December 7, 2009
- Subanalysis Shows Greater Efficacy for Ticagrelor over Clopidogrel: AZ
December 7, 2009
- Cut Total Medical Fees by 3%: MOF
December 7, 2009
- Roche's GLYT-1 Inhibitor Improves Negative Symptoms of Schizophrenia
December 7, 2009
- Over 100 DPJ Legislators Get Together Calling for Increases in Medical Fees
December 7, 2009
- Korosho to Create Team to Discuss How to Promote Development of Cutting-Edge Technology
December 7, 2009
- Astellas Aims at Well-Balanced Growth in 4 Regions: Mr Nogimori
December 7, 2009
- Takepron Applied for Prevention of Ulcers due to NSAIDs
December 7, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…